All In Biotech

Drug Trial Radar · NCT03371979

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

42

Actual

Start

Dec 21, 2017

Primary completion

Jun 11, 2020

Study completion Jun 11, 2020

Sponsor

Lead sponsor
Immedica Pharma ABIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; Aeglea Biotherapeutics
First posted
Dec 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.

Conditions

  • Small-cell Lung Cancer

Interventions

  • PegzilarginaseDrug

    Administered IV

  • PembrolizumabDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of Treatment-realted Adverse Events as Assessed by CTCAE v4.0Time frame: Estimated up to 6 months

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama, Mitchell Cancer Institute

    Mobile, Alabama

  • University of Colorado

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Mid Florida Hematology and Oncology Centers

    Orange City, Florida

  • Woodlands Medical Specialists, PA

    Pensacola, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • University of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University

    St Louis, Missouri

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • The Valley Hospital, Luckow Pavilion

    Paramus, New Jersey

  • Oncology Hematology Care Inc.

    Cincinnati, Ohio

  • Providence Cancer Center

    Portland, Oregon

  • UPMC Cancer Center

    Pittsburgh, Pennsylvania

  • Charleston Hematology Oncology Associates

    Charleston, South Carolina

  • West Clinic

    Germantown, Tennessee

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology-Memorial City

    Houston, Texas

  • Texas Oncology-Tyler

    Tyler, Texas

  • Oncology & Hematology Associates of SW Virginia

    Blacksburg, Virginia

  • Fundacion De Investigacion, Hematology/Oncology

    San Juan, Puerto Rico, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.